Lactose (India) Limited (524202) Fair Value & Analysis
Healthcare · IN · Market cap ₹178M
Fair value as of: Jul 4, 2026
From 14 valuation models · updated today
Share price −9.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹78.19 – ₹131.95 · fair‑value band ₹98.11 – ₹163.63 · the ₹103.75 price screens below the ₹130.91 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lactose (India) Limited (524202) currently trades at ₹103.75, while our model-based Fair Value estimate is ₹130.91 — implying the stock looks roughly 26.2% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Lactose (India) Limited generated revenue of ₹346M at a net margin of -6.7%. Revenue declined 19.4% year over year. It earns a return on equity of -7.0%. Net debt stands at ₹611M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Lactose (India) Limited manufactures and trades in pharmaceutical products in India. The company offers lactose monohydrate; dry granulated, film, and lacquer coated tablets; and pharmaceutical products in liquid dose forms. It also provides disaccharide lactulose, an active pharmaceutical ingredient that is used in the treatment of constipation, hepatitis encephalopathy, intestinal microflora, dental care, diabetes, and chronic liver disease, as well as for use as a prebiotic; and galacto-oligosaccharides, a prebiotic for use in dairy and bakery products, beverages, infant and clinical nutrition, and geriatric nutrition applications, as well as in products for children or adolescents. The company also exports its products to Russia, Kazakhstan, Belarus, Nigeria, Sri Lanka, and other countries. Lactose (India) Limited was founded in 1991 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lactose (India) Limited reported revenue of ₹1.6B in FY2026 versus ₹459M in FY2022, a compound +37.3%/yr. Reported net income was ₹60.6M in FY2026, compounding +25.4%/yr from FY2022.
Is 524202 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹244.55 | ₹96.79 | -60% |
| Anuh Pharma Limited 506260 | ₹80.21 | ₹110.37 | +38% |
| Medicamen Biotech Limited 531146 | ₹262.00 | ₹98.91 | -62% |
| Coral Laboratories Limited 524506 | ₹605.55 | ₹779.49 | +29% |
| Gennex Laboratories Limited 531739 | ₹10.16 | ₹28.19 | +177% |
| Beryl Drugs Limited 524606 | ₹21.22 | ₹17.12 | -19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lactose (India) Limited (524202) undervalued?
What is the fair value of 524202?
What is the quality score of 524202?
What is the revenue of Lactose (India) Limited (524202)?
What is the net profit margin of 524202?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.